How do you read a TRT blood panel?

What is on a Testosterone (TRT) blood panel

A Testosterone (TRT) panel is not one number — it is a small dashboard. The Endocrine Society guideline recommends a standardized monitoring plan that measures serum testosterone and hematocrit during the first year and beyond, alongside symptoms and adverse effects (Bhasin et al., 2018). Most clinics test before starting, then at roughly 1 month, 3–6 months, and annually once stable (StatPearls, Male Hypogonadism).

The markers split into two jobs. Efficacy markers tell you whether the dose is working: total testosterone and free testosterone. Safety markers tell you whether the dose is causing harm: hematocrit (red-cell concentration), estradiol (converted from testosterone), and PSA (prostate). SHBG and albumin are the binding proteins that explain the gap between total and free testosterone — most circulating testosterone is bound to these, and only the unbound fraction acts at the tissue level (StatPearls, Physiology, Testosterone).

Marker-by-marker: what each value means

The table below is a reading guide, not a prescription. Reference ranges differ between labs and assays, so always compare your result to the range printed on your own report rather than a number from a forum.

Read free testosterone alongside SHBG. A "normal" total testosterone with low SHBG can leave a high free fraction, while the same total with high SHBG can leave a free level that still feels low — which is why the active fraction, not just the headline, is what matters.

PSA: ranges, trends, and common misreadings

Prostate-specific antigen (PSA) is a protein made by prostate tissue. A small amount enters the blood and is measured in nanograms per milliliter (ng/mL). PSA is prostate-specific, not cancer-specific: an enlarged or inflamed prostate can also raise it. On TRT, a baseline and later results help a clinician follow changes over time. The number does not measure testosterone dose and does not tell you by itself whether a treatment should change.

There is no single PSA value that means the same thing for everyone. A commonly used set of age-adjusted upper reference points is about 2.5 ng/mL in the 40s, 3.5 in the 50s, 4.5 in the 60s, and 6.5 in the 70s; many labs also use 4 ng/mL as a general reference point. These values come from different screening conventions and are not universal cutoffs, personal targets, or a diagnosis; the AUA/SUO guideline summarizes this commonly used age-varying pattern. (AUA/SUO guideline) Use the range and units printed on the report, and compare results with the same lab when possible. Age, family history, race, prior results, prostate size, and the reason for testing all affect how a clinician interprets a result. The Endocrine Society guideline describes follow-up during the first year of testosterone therapy when a confirmed PSA rise is greater than 1.4 ng/mL above baseline or a confirmed result is above 4 ng/mL; those are referral criteria in that guideline, not universal screening cutoffs. (Endocrine Society guideline)

A trend is often more useful than comparing one result with a generic threshold. PSA velocity is the change in PSA divided by the time between tests, expressed in ng/mL per year:

PSA velocity = (later result − earlier result) ÷ years between tests

For example, if PSA changes from 1.0 to 1.5 ng/mL over one year, the calculation is (1.5 − 1.0) ÷ 1 = 0.5 ng/mL per year. If the same change happens over six months, divide by 0.5 years: 0.5 ÷ 0.5 = 1.0 ng/mL per year. Keep the dates and units with each result; a six-month interval is not one year, and a raw increase cannot be compared fairly without accounting for time.

Velocity is a summary of past measurements, not a forecast. Older sources cite values such as 0.75 ng/mL per year as a point for closer attention, but there is no single velocity threshold that diagnoses cancer or should decide the next test on its own. The AUA/SUO guideline advises clinicians not to use PSA velocity as the sole indication for a biomarker, imaging, or biopsy. A clinician considers the confirmed PSA level, age, history, examination, and other findings together. (AUA/SUO guideline)

Common ways to misread PSA

• Treating one result as a diagnosis. A raised result can have non-cancer causes and may need repeating. Infection or inflammation can affect PSA for weeks; ejaculation and vigorous cycling can raise it temporarily. Follow the lab or clinician's instructions about when to test. (National Cancer Institute)
• Calling a result below 4 “normal.” PSA can be below that level in people with prostate cancer, and a higher value does not prove cancer. The number is one part of an assessment.
• Comparing unlike results. Check that both results use ng/mL and note the dates. Different assays and labs can produce small differences, so use the same lab when practical.
• Ignoring context. Age-related ranges and a person's baseline can help explain a result, but neither is a stand-alone personal target. A modest absolute change can matter differently at different starting values.
• Using velocity as a treatment instruction. The calculation describes a rate of change; it does not say whether to start, stop, or adjust TRT. Discuss a confirmed change with the prescriber who knows the full history.

For useful comparisons, record the value, date, units, lab, and any relevant testing instructions. Ask the clinician how a result fits with prior measurements and whether it should be repeated. PSA interpretation and screening decisions belong with a qualified clinician; this guide explains the arithmetic only.

Why timing changes the number

Injectable esters do not hold a flat level. After a testosterone enanthate injection, serum levels can climb to several times baseline within 8–24 hours, then decline across the rest of the interval (Nieschlag et al., 1984). So the same weekly dose can read "high" two days post-injection and "low" the morning before the next one. A result without a known draw time is hard to interpret.

The fix is consistency. For a once-weekly ester, the conventional draw is the trough — the morning of injection day, before you inject — because that is the lowest, most reproducible point. For more frequent protocols (every 3.5 days, daily microdosing) the peaks and troughs flatten, so the exact draw time matters less, but you should still standardize it.

Hematocrit: the marker injectors watch most

Testosterone stimulates red-blood-cell production, so the most common abnormal value on an injectable-Testosterone (TRT) panel is a rising hematocrit. A narrative review of Testosterone (TRT)-induced erythrocytosis found injectable formulations carry the highest risk of red-cell elevation, with a recognized link to venous thromboembolism (Jones et al., 2015). StatPearls notes testosterone therapy is generally not recommended when hematocrit already exceeds the upper normal limit (StatPearls, Male Hypogonadism).

Practically, this is why a Testosterone (TRT) panel almost always includes a full blood count. A hematocrit drifting toward 52–54% is the usual trigger for a clinician to discuss reducing the dose, increasing injection frequency (smaller peaks), improving hydration before the draw, or other steps — decisions for your prescriber, not this page.

How this is calculated: total vs free testosterone

Most labs report total testosterone directly from an assay, but free testosterone is often estimated from total testosterone, SHBG, and albumin using a binding equation (the Vermeulen method). The arithmetic below shows the logic without the full quadratic — useful for sanity-checking, not for replacing the lab.

So, how do you read a Testosterone (TRT) blood panel?

To read a Testosterone (TRT) blood panel, check total and free testosterone against the lab’s reference range first, then read the safety markers around them — hematocrit, estradiol, SHBG, PSA and a lipid panel — and always draw blood at the same point in your dosing cycle (usually the trough) so results compare. The numbers only mean something in context, so take them to your prescriber rather than self-adjusting. See how total T, SHBG and albumin combine into free testosterone with the free testosterone calculator.

Frequently asked questions